Acadia Pharmaceuticals Stock Fundamentals
| ACAD Stock | USD 16.54 0.17 1.04% |
ACADIA Pharmaceuticals fundamentals help investors to digest information that contributes to ACADIA Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ACADIA Stock. The fundamental analysis module provides a way to measure ACADIA Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ACADIA Pharmaceuticals stock.
At present, ACADIA Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 762.8 M, whereas EBIT is forecasted to decline to (77 M). ACADIA | Select Account or Indicator |
ACADIA Pharmaceuticals Company Current Valuation Analysis
ACADIA Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ACADIA Pharmaceuticals Current Valuation | 2.21 B |
Most of ACADIA Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ACADIA Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ACADIA Current Valuation Historical Pattern
Today, most investors in ACADIA Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ACADIA Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ACADIA Pharmaceuticals current valuation as a starting point in their analysis.
ACADIA Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ACADIA Pharmaceuticals has a Current Valuation of 2.21 B. This is 84.63% lower than that of the Biotechnology sector and 52.47% lower than that of the Health Care industry. The current valuation for all United States stocks is 86.72% higher than that of the company.
ACADIA Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ACADIA Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare ACADIA Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ACADIA Pharmaceuticals competition to find correlations between indicators driving ACADIA Pharmaceuticals's intrinsic value. More Info.ACADIA Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.32 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for ACADIA Pharmaceuticals is roughly 3.14 . At present, ACADIA Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value ACADIA Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ACADIA Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ACADIA Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ACADIA Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ACADIA Pharmaceuticals by comparing valuation metrics of similar companies.ACADIA Pharmaceuticals is currently under evaluation in current valuation category among its peers.
ACADIA Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ACADIA Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ACADIA Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ACADIA Fundamentals
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 2.21 B | ||||
| Shares Outstanding | 166.39 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 97.10 % | ||||
| Number Of Shares Shorted | 9.53 M | ||||
| Price To Earning | (13.77) X | ||||
| Price To Book | 4.72 X | ||||
| Price To Sales | 2.93 X | ||||
| Revenue | 726.44 M | ||||
| Gross Profit | 145.49 M | ||||
| EBITDA | (67.83 M) | ||||
| Net Income | (61.29 M) | ||||
| Cash And Equivalents | 436.35 M | ||||
| Cash Per Share | 2.70 X | ||||
| Total Debt | 57.2 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | 3.47 X | ||||
| Cash Flow From Operations | 16.7 M | ||||
| Short Ratio | 8.43 X | ||||
| Earnings Per Share | 0.78 X | ||||
| Price To Earnings To Growth | (0.42) X | ||||
| Target Price | 25.11 | ||||
| Number Of Employees | 620 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 2.72 B | ||||
| Total Asset | 748.96 M | ||||
| Retained Earnings | (2.43 B) | ||||
| Working Capital | 361.87 M | ||||
| Current Asset | 603.49 M | ||||
| Current Liabilities | 39.15 M | ||||
| Net Asset | 748.96 M |
About ACADIA Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACADIA Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACADIA Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACADIA Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.4 M | 1.3 M | |
| Total Revenue | 726.4 M | 762.8 M | |
| Cost Of Revenue | 45.7 M | 25.4 M | |
| Stock Based Compensation To Revenue | 0.09 | 0.09 | |
| Sales General And Administrative To Revenue | 0.54 | 0.51 | |
| Research And Ddevelopement To Revenue | 0.48 | 0.46 | |
| Capex To Revenue | 0.05 | 0.05 | |
| Revenue Per Share | 4.43 | 4.66 | |
| Ebit Per Revenue | (0.10) | (0.11) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:Check out ACADIA Pharmaceuticals Piotroski F Score and ACADIA Pharmaceuticals Altman Z Score analysis. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share 5.622 | Quarterly Revenue Growth 0.183 | Return On Assets 0.0872 |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.